Early Stage Life Sciences and Healthcare in Europe
The European investment ecosystem is thriving more than ever. The challenges highlighted by lockdowns led to a flourishing of innovation and of sources of funding for our ecosystems.
The European ecosystem is deployed in the past 12 months over $1.3bn invested in early-stage life sciences and healthcare.
The life sciences and healthcare space has been moving from stride to stride in the upward direction, and it is predicted to be bigger than ever. It is fueled by the institutional capital able to be deployed in VC funds. Healthcare is at the top of the agenda for every state, every local authority and every healthcare provider whether private or public.
While 2020 has been a record year, the $17bn raised by funds last year will have to be channelled into new emerging technologies and solutions.
Unlike other major jurisdictions such as the US or China, I am observing a split focus between Health Tech, Biopharma and Device (mainly focusing on Surgical and therapeutical uses). Less of a focus on Diagnostic Tools or technologies.
A major question to be asked is what Digital Health in Europe going to look like in a few years based on what we are investing in today.
Across Europe we over 1200 rounds at Pre-Seed, Seed, and Early VC (pre-Series A). It has been on an upward trajectory for a number of years.
Two major areas of focus for our ecosystems
- Technologies focusing mostly on clinical decisions. These are AI / Ml applications (distinguishing from diagnostics) mean to help the digitalisation of doctor/clinician-patient relationship for various indications. Unlike the US we do not have any hybrid virtual and in-person providers. Across…
